

Figure 4-figure supplement 1. (A) *In vitro* kinase assay of tandem-affinity purified MAP4K4 (Flag/HA) from HEK TER cells expressing either ST or GFP was performed and MBP was used as a substrate. HA and phospho-MBP were detected by immunoblotting. (B) *In vitro* MAP4K4 kinase assay from HEK TER cells using increasing concentrations of the MAP4K4 inhibitor (Compound 29). MBP was used as substrate and phosphorylation determined by phospho-MBP immunoblotting (bottom). Quantification of relative kinase activity (top). (C) Proliferation of HEK TER cells was measured after exposure to compound 29 at the indicated concentrations. Student's t-test was performed based on absorbance values measured between 0 uM and 1 uM at 5 days. (D) Representative immunoblot showing MAP4K4 *in vitro* kinase assay using tandem-affinity purified wild-type (WT) or kinase-dead mutant (K54R) MAP4K4. (E) Mean MAP4K4 activity of WT relative to kinase-dead mutant (K54R) assessed using *in vitro* kinase assay (student's t-test: n.s.= not significant, **p<0.001, ***p<0.0001).